Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer’s disease-Reference-Cited by-同舟云学术

Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer’s disease

Published:2019-02-12 Issue:1 Volume:11 Page:
ISSN:1758-9193
Container-title:Alzheimer's Research & Therapy
language:en
Short-container-title:Alz Res Therapy

Author:

Frölich Lutz,Wunderlich Glen,Thamer Claus,Roehrle Michael,Garcia Miguel,Dubois Bruno

Publisher

Springer Science and Business Media LLC

Subject

Cognitive Neuroscience,Neurology (clinical),Neurology

Link

http://link.springer.com/content/pdf/10.1186/s13195-019-0467-2.pdf

Reference22 articles.

1. Alzheimer's Association. 2016 Alzheimer’s disease facts and figures. Alzheimers Dement. 2016;12(4):459–509.

2. Fiest KM, et al. The prevalence and incidence of dementia due to Alzheimer’s disease: a systematic review and meta-analysis. Can J Neurol Sci. 2016;43(Suppl 1):S51–82.

3. Dubois B, et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol. 2010;9(11):1118–27.

4. Lee HG, et al. Differential regulation of glutamate receptors in Alzheimer’s disease. Neurosignals. 2002;11(5):282–92.

5. Bales KR, et al. Phosphodiesterase inhibition to target the synaptic dysfunction in Alzheimer’s disease. Topics Med Chem. 2010;6:57–90.

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design of Multi-Target drugs of HDACs and other Anti-Alzheimer related Targets: Current strategies and future prospects in Alzheimer’s diseases therapy;Bioorganic Chemistry;2024-10

2. The therapeutic potential of phosphodiesterase 9 (PDE9) inhibitors: a patent review (2018-present);Expert Opinion on Therapeutic Patents;2024-07-09

3. Opportunities and perspectives of small molecular phosphodiesterase inhibitors in neurodegenerative diseases;European Journal of Medicinal Chemistry;2024-05

4. Emerging phosphodiesterase inhibitors for treatment of neurodegenerative diseases;Medicinal Research Reviews;2024-01-27

5. Review on anti-alzheimer drug development: approaches, challenges and perspectives;RSC Advances;2024